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The Leptin Receptor Complex: 
Heavier Than Expected?
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1 Cytokine Receptor Laboratory, Faculty of Medicine and Health Sciences, Department of Biochemistry, Ghent University, 
Ghent, Belgium, 2 VIB Medical Biotechnology Center, VIB, Ghent, Belgium
Under normal physiological conditions, leptin and the leptin receptor (ObR) regulate 
the body weight by balancing food intake and energy expenditure. However, this 
adipocyte-derived hormone also directs peripheral processes, including immunity, 
reproduction, and bone metabolism. Leptin, therefore, can act as a metabolic switch 
connecting the body’s nutritional status to high energy consuming processes. We pro-
vide an extensive overview of current structural insights on the leptin–ObR interface and 
ObR activation, coupling to signaling pathways and their negative regulation, and leptin 
functioning under normal and pathophysiological conditions (obesity, autoimmunity, 
cancer, … ). We also discuss possible cross-talk with other receptor systems on the 
receptor (extracellular) and signaling cascade (intracellular) levels.
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INTRODUCTION
The identification of two spontaneous obese mouse strains at the Jackson Laboratory, ob/ob mice in 
1950 and db/db mice in 1965, were the first steps toward the discovery of the leptin–ObR system. A 
series of elegant parabiosis experiments illustrated that db/db mice overexpressed a strong circulat-
ing satiety factor to which they cannot respond themselves. On the other hand, ob/ob animals do not 
produce this factor but lose weight when parabiotically paired to wild-type or db/db mice (1). This 
Abbreviations: ACC, acetyl-CoA carboxylase; AgRP, agouti-related peptide; AMPK, adenosine monophosphate-activated 
protein kinase; α-MSH, α-melanocyte stimulating hormone; AR, amphiregulin; ARC, arcuate nucleus; BBB, blood–brain bar-
rier; BBS, Bardet–Biedl syndrome; BP, blood pressure; BRET, bioluminescence resonance energy transfer; CNS, central nervous 
system; CRH, cytokine receptor homology domain; EGF, epidermal growth factor; EGFR, EGF receptor; EPR, epiregulin; 
ER, endoplasmic reticulum; ERK, extracellular signal-related kinase; FN III, fibronectin type III; Foxo1, forkhead box O1; 
FRET, fluorescence resonance energy transfer; GABA, γ-aminobutyric acid; G-CSF, granulocyte-colony stimulating factor; 
Grb2, growth factor receptor-bound protein 2; GRP78, glucose-regulated protein 78; GSK3β, glycogen synthase kinase 3β; 
HB-EGF, heparin-binding EGF-like growth factor; HFD, high-fat diet; HUVEC, human umbilical vein endothelial cell; ICV, 
intracerebroventricular; IGD, immunoglobulin-like domain; IGF-IR, insulin-like growth factor I receptor; IL, interleukin; IR, 
insulin receptor; IRS, insulin receptor substrate; JAK, Janus kinase; LEPROT, leptin receptor overlapping transcript; LRP, lipo-
protein receptor-related protein; MALLS, multi-angle laser light scattering; MAPK, mitogen-activated protein kinase; MBH, 
medio-basal hypothalamus; MFN2, mitofusin 2; mTOR, mammalian target of rapamycin; NOS-1, nitric oxide synthase-1; NPY, 
neuropeptide Y; NTD, N-terminal domain; ObR, leptin receptor; PDE3B, phosphodiesterase 3B; PDK1, 3-phosphoinositide-
dependent protein kinase; PI3K, phosphatidylinositol 3 kinase; PIP3, phosphatidylinositol 3,4,5-triphosphate; POMC, 
pro-opiomelanocortin; PRMT2, protein arginine N-methyltransferase 2; PTEN, tumor suppressor phosphatase and tensin 
homology; PTP, tyrosine phosphatase; PTP1B, protein tyrosine phosphatase 1B; RNF41, ring finger protein 41; RPGRIP1L, 
retina pigmentosa GTPase regulator-interacting protein-1; S6K, S6 kinase; SAXS, small-angle X-ray scattering; SHP2, SH2-
containing protein tyrosine phosphatase 2; SOCS, suppressor of cytokine signaling; STAT, signal transducer and activator of 
transcription; TGF-α, transforming growth factor-α; TLR, toll-like receptor; TNF-α, tumor necrosis factor-α; UPR, unfolded 
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factor was cloned 40 years later by Friedman and colleagues as the 
product of the ob gene and called leptin after the Greek “leptos” 
meaning thin (2). The product of the db gene was identified as the 
ObR using an expression-cloning strategy based on the ability to 
bind leptin (3).
LEPTIN
Leptin, a hormone with cytokine-like characteristics, is mainly 
but not exclusively produced by adipose tissue in a way that its 
levels positively correlate with the energy stored in the body 
(4–6). Other sources of (lower) leptin expression include pla-
centa, stomach, mammary epithelium, and skeletal muscle (7–9). 
Mature leptin is a non-glycosylated 16 kDa protein of 146 amino 
acids. The crystal structure at 2.4 Å resolution of leptin W110E, 
a mutation that dramatically increases solubility of the protein 
without affecting biological activity, shows a typical four-helical 
bundle structure. Four anti-parallel α-helices (A, B, C, and D) in 
an up-up-down-down arrangement are connected by one short 
(BC) and two long (AB and CD) loops. Leptin has two conserved 
cysteine residues (one in the CD loop and the C-terminal residue) 
that form a solvent-exposed disulfide bridge that tethers the CD 
loop to the C-terminal part of helix D. This disulfide bridge is 
crucial for structural stability, secretion, and biological activity 
(10, 11). These structural characteristics strongly resemble those 
found in granulocyte-colony stimulating factor (G-CSF) and 
interleukin-6 (IL-6) cytokines, and leptin is, therefore, classified 
as a long-chain cytokine.
LEPTIN RECEPTOR
ObR is a single membrane-spanning receptor belonging to 
the class I cytokine receptor family (3). Up to now, six ObR 
isoforms are produced by alternative splicing or ectodomain 
shedding: ObRa–ObRf. These include one long form (ObRb; 
with an intracellular domain of 302 Aa); four short forms (ObRa, 
ObRc, ObRd, and ObRf, with cytoplasmic tails of 30–40 Aa 
with unique C-termini); and one soluble form (ObRe). ObRb 
contains three highly conserved tyrosine residues (Y985, Y1077, 
Y1138) required for efficient leptin signaling. ObRb is highly 
expressed in specific nuclei of the hypothalamus, a region of 
the brain involved in the regulation of body weight (12–14). 
Expression at functional levels can also be detected in a broad 
range of other cell types, in line with the pleiotropic effects of 
leptin (see further). Their expression pattern suggests that the 
short ObR’s play a role in transport of leptin over the blood–brain 
barrier (BBB) (15) and/or renal clearance (3). The soluble ObRe 
isoform, directly secreted in mice while in humans generated 
by ectodomain shedding (16, 17), modulates bio-availability of 
the hormone (18). All isoforms have an identical extracellular 
part consisting of six domains: an N-terminal domain (NTD), 
two CRH domains (CRH1 and CRH2), an immunoglobulin-
like domain (IGD), and two additional membrane-proximal 
fibronectin type III (FN III) domains. This overall architecture 
of the extracellular domain and the sequence similarity resemble 
that of the G-CSF and gp130-related receptors. The ObR is heav-
ily glycosylated causing an increase of 30–70 kDa in molecular 
weight (19, 20). N-glycosylation is predominant with 18 of 20 
NXS motifs in the human receptor glycosylated, although some 
O-glycosylation is also present (19). N-glycanase F treatment 
reduces leptin binding of recombinant ObR extracellular domain 
by 80%, illustrating the importance of this type of modification 
in this process (20).
LEPTIN BIOLOGY AND DISEASE
As mentioned above, loss-of-function mutations in the leptin or 
ObR genes (2, 21–23) or genetic ablation of leptin’s central signal-
ing (16, 24) results in severe, early-onset obesity (25). To date, 
leptin and its receptor are the most crucial of factors identified, 
which control body weight by balancing food intake and energy 
expenditure in the adaptive response to altered energy states like 
fasting or starvation. As a product of adipose tissue, it signals the 
energy stored in the body and thereby functions as a negative 
feedback adipostat, an efferent satiety signal and an anti-obesity 
hormone.
In 2014, more than 1.9 billion adults were overweight (BMI 
levels 25–29 kg/m2), and of these, over 600 million were obese 
(BMI levels 30 kg/m2 and greater), making obesity and the asso-
ciated metabolic syndrome a major health problem worldwide. 
It is a complex medical condition caused by an accumulation 
of excess body fat (calorie intake exceeds calorie expenditure) 
leading to negative effects on health including type 2 diabetes, 
heart diseases, obstructive sleep apnea, cancer, and joint disease. 
Obesity is caused by the interplay between environmental, 
genetic, and epigenetic factors. To date, not less than 50 genes 
(including leptin, ObR, and mediators of leptin signaling) are 
related to an increased obesity risk in humans and rodents (26). 
Paradoxically, levels of biologically active leptin are elevated in 
most obese subjects, and these patients do not respond to leptin 
treatment. Mechanisms underlying this “leptin resistance” are 
discussed later.
Leptin or ObR deficiencies not only cause severe obesity but 
also abnormalities in hematopoiesis (27), immunity (28), repro-
duction (29), angiogenesis (30), bone formation (31), and blood 
pressure (BP) (32). This lead to the concept that leptin can act as 
a “metabolic switch” that links the body’s energy stores to these 
high-energy demanding processes (33).
Ozata and colleagues were the first to report that seven 
members of a Turkish family with congenital leptin deficiency 
died during childhood due to infections pointing to a role for 
leptin in human immunity (34). Along the same line, leptin 
treatment of two children with congenital leptin deficiency (35) 
and in females with acquired hypoleptinemia (36) normalized 
absolute T cell numbers and nearly restored T cell proliferation 
responses and cytokine release profiles. Over the past decade, 
leptin emerged as a regulator of multiple cell types of both innate 
and adaptive immune responses (37). In innate immunity, leptin 
controls the activation of macrophages, neutrophils, monocytes, 
dendritic, and natural killer cells and promotes the production 
of pro-inflammatory cytokines. Thymic and splenic homeosta-
sis, naïve CD4+ cell proliferation, promotion of TH1 responses, 
suppression of regulatory T cells, and activation of TH17 cells 
are the most important functions in adaptive immunity (37). 
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Its pro-inflammatory characteristics link leptin to the onset and 
progression of several autoimmune diseases, including multiple 
sclerosis (38), antigen-induced arthritis (39), hepatitis (40, 41), 
colitis (41), and glomerulonephritis (42). Leptin-deficient rodents 
are often protected in experimental models for these diseases, 
while leptin administration restores sensitivity.
The observations that humans and rodents with congenital 
leptin deficiencies are sterile and that anorexia and obesity delay 
and accelerate the onset of puberty, respectively, led to the idea 
that leptin is an important player in reproduction (43). The 
hormone functions both directly on the ovaries and indirectly 
via gonadotrophin-releasing hormone, luteinizing hormone, or 
kisspeptin release (44).
Ob/ob and db/db mice display significant longer vertebral 
length and have higher bone mass (31). Leptin influences bone 
metabolism via central and peripheral pathways [reviewed in Ref. 
(45)]: it suppresses osteoblast proliferation and promotes osteo-
clast resorption through activation of neurons in the ventromedial 
hypothalamus. More direct effects include proliferation, survival, 
differentiation, or suppression of bone marrow mesenchymal 
stem cells, osteoblasts, osteoclasts, and chondrocytes, and the 
synthesis of collagen and extracellular matrix proteins.
Leptin affects BP in an apparently opposite way: on the one 
hand it causes chronic increase in BP and may contribute to obe-
sity related hypertension, while on the other hand its metabolic 
actions (lowering appetite and increasing energy expenditure) 
tend to reduce BP (46).
Excess body fat in obesity can contribute to the development of 
cancer. Etiological causes not only include elevation of estrogen, 
insulin, insulin-like growth factors, leptin but also local inflamma-
tion and depressed immune function seen with excess adiposity. 
Elevated leptin levels are linked to an increased risk of myeloma 
(47) and of prostate (48), breast (49), colorectal (50), and renal 
(51) cancers. Leptin not only promotes survival and proliferation 
of several cancer cell lines directly but also promotes adhesion, 
invasion, metastasis (via upregulation of metalloproteinases, 
E-cadherin, and extracellular matrix proteins), and angiogenesis 
(via vascular endothelial growth factor and its receptor) in the 
tumor environment (52).
ObR ACTIVATION
Only a minor fraction of the ObR (10–20%) is expressed at the cel-
lular surface, while the majority is found in intracellular compart-
ments, including endoplasmic reticulum (ER), trans-Golgi, and 
endosomes (53). This subcellular distribution is the result of the 
partial retention of the receptor in the biosynthesis pathway and 
the constitutive, ligand-independent endocytosis of the receptor 
(see also further). Furthermore, co-immunoprecipitation of dif-
ferentially tagged ObR’s (54, 55) or the high basal signal in the 
absence of leptin in bioluminescence resonance energy transfer 
(BRET) (56) and fluorescence resonance energy transfer (FRET) 
(57) suggests that the ObR forms pre-formed dimers (or oligom-
ers) on the cellular surface. Numerous cytokine receptors can 
form these inactive, pre-formed receptor complexes, including 
the erythropoietin receptor (58–60), the growth hormone recep-
tor (61), and the IL-6 receptor (62). Earlier studies suggested 
this oligomerization also in solution (63, 64), but more recent 
multi-angle laser light scattering and small-angle X-ray scattering 
(SAXS) show that the soluble ObRe is a monomer in the absence 
of leptin (65, 66).
ObR activation depends on the CRH2, IGD, and FN III domains 
(Figure 1). The ObR CRH2 domain is the major leptin-binding 
determinant in the receptor (67, 68). Depending on the technique 
and proteins used, CRH2 binds leptin with a KD of 0.2–15 nM in 
solution or 0.2–1.5 nM on the cellular surface [reviewed in Ref. 
(69)]. The binding affinity to the isolated CRH2 domain or to the 
complete extracellular domain is comparable, illustrating that this 
domain is indeed strictly required and sufficient (67, 70). A region 
of four consecutive hydrophobic residues has been identified as 
the leptin-binding site in the CRH2 domain (71, 72). The crystal 
structure of the CRH2 domain, in complex with a Fab fragment of 
a neutralizing Ab, was determined at 1.95 Å resolution (73). This 
is the first and, hitherto, the only high-resolution structure for 
(a part of) the ObR. The IGD and membrane-proximal domains 
have no detectable affinity for the ligand, but are nonetheless 
indispensable for receptor activation. Deletion of the IGD results 
in a receptor with wild-type affinity for leptin, but completely 
devoid of biological activity (67, 68). A conserved surface patch 
in the β-sheet formed by β-strands 3, 6, and 7 was identified as 
the leptin-binding site in this domain (74). Leptin contains a 
binding site (III) which allows contact with the IGD of a second 
ObR, thereby inducing dimerization and potential higher-order 
clustering with evidence for a 2:4 leptin:ObR hexameric structure 
(74). In the FN III domains, two conserved cysteine are crucial for 
receptor activation since combined mutation completely blocks 
activation of the receptor (64). Finally, deletion of the NTD and 
CRH1 domains hardly affects ObR functionality (67, 68). This 
seems in contrast to the obese phenotype of fatty Zucker rats 
resulting from the Q269P mutation in the CRH1 domain (75). 
Likewise, the naturally occurring single-nucleotide polymor-
phism Q223R causes obesity in Brazilian multiethnic subjects 
(76) and the increased susceptibility toward protozoan infections 
in children (77).
Based on the structural and evolutionary relationship of leptin 
and its receptor with the G-CSF and IL-6 receptor systems, we 
selected and tested a panel of leptin mutants and thereby identi-
fied three putative receptor-binding sites (78). Mutations in bind-
ing site I (located at the C terminus of helix D) moderately affect 
binding and signaling. Binding site II residues (at the surface of 
helices A and C) are crucial for binding to the CRH2 domain, but 
mutations in this region have only limited effect on signaling (78). 
Two regions were independently proposed as the binding-site III, 
which interacts with the ObR IGD: the area around residues S120 
and T121 at the N terminus of helix D (78) and the 39-LDFL-42 
stretch in the AB loop (79). Mutation of either area is sufficient to 
create leptin antagonists in vitro and in vivo (78, 79).
Both 3D reconstructions of 2D negative-stain EM images by 
Mancour et al. (65) and the SAXS experiments by Moharana et al. 
(66) point to an analog 2:2 quaternary core leptin:ObR complex. 
In this model, leptin binds with its site II to the CRH2 domain of a 
first ObR and engages a second receptor via the site III–IGD inter-
action. Additional receptor–receptor interactions (e.g., between 
FN III domains) that occur at the cell surface, but not in solution, 
FIGURE 1 | The activated leptin:ObR complex. Leptin clusters two pre-formed ObR dimers to form an activated 2:4 leptin:ObR complex. In this model, the 
ObR’s are colored green and red, leptin molecules cyan. The hormone binds with its binding site II to the CRH2 domain of the receptor, while site III residues interact 
with the immunoglobulin-like domain (IGD) of a second receptor. These residues are colored yellow and green, and defined in the cyan panel. Receptor residues 
involved in these interactions are shown in the red and green panels. For reasons of clarity, only the CRH2 and IGD domains of each receptor are shown.
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could lead to 2:4 or 4:4 leptin:ObR complexes. This higher-order 
clustering would be in line with our signaling-complementation 
assay (68). Finally, leptin stimulation increases BRET and FRET 
signals (see above), suggesting that reorganization within the pre-
formed complexes and/or de novo oligomerization likely occur 
(56, 57).
ObR SIGNALING
The ObRb is mainly expressed by two distinct neuronal popula-
tions in the hypothalamic arcuate nucleus (ARC): the anorexigenic 
(appetite-depressing) POMC (pro-opiomelanocortin) neurons 
and the orexigenic (appetite-promoting) NPY/AgRP (neuro-
peptide Y/agouti-related peptide) neurons (80, 81) (Figure 2). 
ObRb activation in POMC neurons triggers POMC expression, a 
precursor peptide, that is further converted by prohormone con-
vertases to α-melanocyte stimulating hormone (αMSH), which is 
secreted and signals by activating melanocortin receptors, MC3R, 
and MC4R. Deletion of MC3R and/or MC4R results in leptin 
resistance and obesity (82, 83). Specific reconstitution of ObRb 
expression in POMC neurons of ObRb-deficient mice not only 
modestly reduces body weight but also completely normalizes 
blood glucose levels, insulin sensitivity, and locomotor activity, 
indicating that leptin signaling in POMC neurons has a key role 
in regulating glucose homeostasis (84, 85). In contrast to POMC 
neurons, leptin suppresses the activity of NPY/AgRP neurons and 
the associated secretion of its orexigenic neuropeptides. AgRP is 
a potent antagonist of αMSH. Moreover, NPY/AgRP neurons 
innervate POMC neurons and inhibit POMC neuronal firing by 
releasing GABA (γ-aminobutyric acid) (86, 87). Selective dele-
tion of ObRb in POMC or NPY/AgRP neurons only gives rise to 
a mild obese phenotype indicating that also other regions in the 
brain are involved in the control of energy homeostasis by leptin 
(88–90).
The JAK/STAT Pathway
The JAK/STAT (Janus kinase/Signal transducers and activators 
of transcription) pathway is probably the best explored pathway 
FIGURE 2 | Signaling pathways of leptin and its downstream effectors. ObR oligomerization (here only dimerization shown for reasons of clarity) results in 
phosphorylation and activation of cytoplasmic associated JAK2 kinases. These activated JAKs phosphorylate tyrosine residues in the cytoplasmic tail of the 
receptor. Recruitment and activation of secondary signaling molecules allow ObR signaling via the JAK/STAT, MAPK, PI3K, AMPK, and mTOR pathways. See text 
for more details.
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activated by leptin. Upon ligand binding and JAK2 activation, the 
conserved ObRb phosphotyrosine 1138 motif serves as a binding 
site for the SH2 domain of STAT3. STAT3 itself will subsequently 
become phosphorylated by the JAKs on Y705 and translocate as 
dimers to the nucleus, where it will modulate expression of several 
STAT3-responsive target genes, such as Suppressor of cytokine 
signaling 3 (SOCS3) (91, 92). SOCS3 acts as a potent negative 
regulator of the JAK/STAT pathway, thereby forming a negative 
feedback loop (93). The negative regulation of ObR signaling will 
be further discussed in the following section.
Experiments with neuron-specific STAT3−/− mice have 
pinpointed the essential role of STAT3 for the acute anorectic 
actions of leptin (94–96). Mice in which STAT3 is specifically 
deleted in ObRb neurons similary develop hyperphagic obesity 
with some preservation of glucose homeostasis (97). However, 
despite the fact that the POMC promotor has a STAT3-responsive 
element and that deletion of STAT3 in POMC neurons com-
pletely diminishes POMC induction, POMC-specific STAT3 
knock-down did not completely abrogate the anorexigenic effect 
of leptin and only leads to a mild obese phenotype (98, 99). This 
indicates that also other signaling pathways in POMC neurons 
are involved in the energy homeostatic response to leptin and/or 
STAT3-dependent effects in other, non-ARC cells are involved. 
Likewise, genetic inactivation of STAT3 in NPY/AgRP neurons 
leads to mild hyperphagia, a decreased response to leptin and 
increased levels of basal NPY expression, while AgRP expression 
remains unaltered (100, 101).
Substitution of tyrosine 1138 with serine (s/s mice) disrupts 
STAT3 recruitment to the ObRb. S/s mice are, therefore, hyper-
phagic and obese, similar to db/db mice and show a suppression 
of melanocortin activity. However, s/s mice are less hyperglycemic 
and show normal fertility, indicating that STAT3-independent 
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pathways control leptins’ effects on reproduction and glucose 
metabolism (102–104).
In addition to phosphorylation, leptin-induced STAT3 meth-
ylation by protein arginine N-methyltransferase 2 (PRMT2) was 
also shown to occur, and PRMT2−/− mice are lean, hypophagic, 
have reduced serum leptin levels and are more resistant to 
diet-induced obesity (DIO) compared to wild-type littermates 
(105). More recently, it was demonstrated that the nuclear recep-
tor Nur77 (or TR3) facilitates STAT3 acetylation by recruiting 
acetylase p300 to and dissociating deacetylase HDAC1 (histone 
deacetylase 1) from STAT3, thereby enhancing the transcriptional 
activity of STAT3 and the expression of POMC (106).
Next to STAT3, leptin also activates STAT1, STAT5, and 
STAT6 in cell culture (107, 108). However, only leptin-dependent 
hypothalamic STAT5 phosphorylation was observed in vivo (109, 
110). Activated STAT5 binds to pY1077, and to lesser extent 
pY1138 of the ObRb (111, 112). ObRb Y1077 mutants show 
only mildly increased food intake and adiposity. Furthermore, 
female mice display impairments in estrous cycling, suggesting 
that signaling by ObRb Y1077 plays only a modest role in the 
control of metabolism by leptin, while it may link body adiposity 
to the reproductive axis (113). However, deletion of STAT5 in 
ObRb expressing cells has no effect on body weight and fertility 
(114), indicating that neither STAT3 nor STAT5 are required 
for the regulation of fertility by leptin and that other signaling 
pathways depending on Y1077 might be involved in the leptin’s 
reproductive functions.
The MAPK Pathway
As mentioned before, the ObRb has three conserved tyrosine 
residues of which the pY985 motif serves as a docking site for the 
C-terminal SH2 domain of SHP2 (SH2-containing protein tyros-
ine phosphatase 2) (115–117). On its turn, SHP2 will become 
phosphorylated by the JAKs and recruit the adaptor protein Grb2 
(growth factor receptor-bound protein 2), which ultimately leads 
to the activation of the mitogen-activated protein kinase (MAPK) 
extracellular signal-regulated kinase 1/2 (ERK1/2) (115, 118, 
119). The phosphatase activity of SHP2 is necessary for leptin-
mediated ERK activation (115). Weaker ERK activation by the 
short isoform ObRa (independent of Y985) was also shown, most 
likely via direct binding of Grb2 to JAK2 (120).
Neuron-specific deletion of SHP2 or pharmacological inhibi-
tion of ERK1/2 in the hypothalamus blocks the anorectic effects 
of leptin (118, 119). Furthermore, POMC-specific deletion of 
SHP2 results in mild obesity and increased susceptibility to DIO 
(121, 122), while female mice expressing a constitutively active 
form of SHP2 in the brain are resistant to DIO (123), supporting 
the role for SHP2 in the control of energy homeostasis. However, 
since SHP2 participates in many signaling pathways, the specific 
contribution of SHP2 downstream the ObRb remains difficult to 
assess. Mice with a mutation in Y985 are neuroendocrinologi-
cally normal and fertile, but especially female mice demonstrate 
decreased hypothalamic AgRP expression, increased pSTAT3 
levels and leptin sensitivity, and resistance to DIO (124). Young 
homozygous Y985F mice were shown to be slightly leaner, 
although they exhibit adult-onset obesity (125). These data most 
likely do not reflect the role of Y985 in leptin-dependent ERK 
activation, but are consistent with increased ObRb signaling due 
to decreased feedback inhibition via disruption of SOCS3 bind-
ing (see further).
The PI3K–Akt–Foxo1 Pathway
A crucial role for the PI3K (phosphatidylinositol 3-OH kinase) 
pathway in leptin signaling was first demonstrated when intrac-
erebroventricular (ICV) injection with PI3K inhibitors inhibited 
leptin’s anorexigenic effects (126). However, the activation 
mechanism is difficult to dissect since no ObRb phoshotyrosine 
site has been identified that mediates PI3K activation. Also, 
the PI3K pathway is shared with other receptors, especially 
the insulin receptor (IR). This hinders the evaluation of the 
ObRb-specific contribution of PI3K in the control of energy 
homeostasis. Although there is evidence that PI3K activation 
mediates the acute effects of leptin on the neuroelectrical activity 
of POMC cells and that the acute responses to leptin and insulin 
are largely segregated in distinct POMC subpopulations (127, 
128). Nevertheless, mice with impaired PI3K signaling in POMC 
neurons have normal body weight, indicating that the PI3K 
pathway in these neurons is not critical for the leptin-mediated 
regulation of energy homeostasis (128).
Insulin receptor substrate 1, and particularly IRS2 are recruited 
to the ObRb via SH2B1, which interacts and upregulates the 
kinase activity of JAK2 (129, 130). SH2B1−/− mice display hyper-
phagia and severe early-onset obesity (131). Neuron-specific 
restauration of SH2B1 rescues this phenotype and improves 
leptin-dependent signaling and neuropeptide expression in the 
hypothalamus (132, 133). Alternatively, IRS4 was also shown to 
recruit the PI3K regulatory p85 subunit via the Y1077 motif of 
the ObRb (134).
IRS proteins in turn bind the PI3K p85 subunit, leading to 
PI3K activation and the accumulation of PIP3 (phosphatidylino-
sitol 3,4,5-triphosphate). This leads to the sequential activation 
of PDK1 (3-phosphoinositide-dependent protein kinase 1) and 
Akt, resulting in the inhibition of the transcription factor Foxo1 
(Forkhead Box O1). Foxo1 mediates the anorectic effects of 
leptin by regulating the expression of POMC, AgRP, and NPY 
(135–138). Foxo1 (when activated) stimulates the transcription 
of AgRP and NPY, but suppresses the transcription of POMC; 
thereby antagonizing the transcriptional action of STAT3 in these 
hypothalamic subpopulations. Recently, it was shown that direct 
interaction of Foxo1 to STAT3 was responsible for the inhibition 
of STAT3-mediated leptin signaling (137, 139). Therefore, mice 
with POMC-specific PDK1 or Foxo1 depletion are less or more 
sensitive, respectively, to the anorectic effects of leptin (140, 141). 
Likewise, Foxo1 ablation in AgRP neurons results in reduced food 
intake, improved glucose homeostasis, and increased sensitivity 
to leptin (142).
As mentioned above, PI3K activity leads to PIP3 accumulation. 
PTEN (tumor suppressor phosphatase and tensin homology) 
promotes the opposite reaction via its lipid phosphatase activity. 
PTEN ablation in ObRb-expressing neurons induces enhanced 
PI3K activity and reduced body fat (143). On the other hand, 
POMC-specific PTEN−/− mice develop leptin resistance and obe-
sity, suggesting that chronic elevation of PIP3 in POMC neurons 
may interfere with hypothalamic leptin activity (144).
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Another target activated downstream of PI3K/Akt is mTOR 
(mammalian target of rapamycin), an evolutionally conserved 
serine/threonine kinase, which senses nutrient availability and 
stimulates protein synthesis, cell growth, and proliferation. 
Leptin stimulates the phosphorylation of p70 S6 kinase (S6K) 
via mTOR. Selective inhibition/deletion of mTOR or S6K in the 
hypothalamus attenuates leptin’s anorexigenic effects (145–147). 
Additionally, PDE3B (phosphodiesterase 3B) is expressed in 
ObRb-expressing neurons in the hypothalamus (148). Leptin 
induces PDE3B activity, which results in a decrease in cAMP 
levels via the PI3K pathway. Inhibition of PDE3B activity by cilos-
tamide reverses leptin’s effects on food intake and body weight, 
as well as the leptin-induced increase in POMC expression in the 
hypothalamus (149, 150).
The AMPK Pathway
Like mTOR, adenosine monophosphate-activated protein kinase 
(AMPK) serves as an intracellular fuel sensor and is activated 
by elevated AMP/ATP ratios. AMPK is a heterotrimeric serine/
threonine kinase consisting of a catalytic α subunit and regulatory 
β and γ subunits. Leptin regulates AMPK activity in a tissue-
specific way: leptin activates AMPK in hepatocytes and muscle 
tissue (151, 152), while in the hypothalamus, leptin inhibits 
AMPK, hence reducing food intake and body weight (153, 154). 
A reduction in AMPK phosphorylation (at T172), observed upon 
leptin treatment, is followed by decreased phosphorylation and 
increased activation of the AMPK target, acetyl-CoA carboxy-
lase (ACC), a key enzyme in fatty acid biosynthesis (155, 156). 
Dominant negative AMPK expression in the hypothalamus is suf-
ficient to reduce food intake and body weight, while constitutively 
active AMPK attenuates leptin’s anorexigenic effects (153, 155).
The precise mechanism of leptin-mediated AMPK activa-
tion is still unclear but requires JAK2 activity and does not 
seem to depend on intracellular phosphotyrosine motifs in the 
ObRb (152). Of the two catalytic subunits, α1 and α2, leptin 
predominantly appears to modulate AMPK activity via alterna-
tive phosphorylation sites in the α2 subunit (153, 157). In the 
hypothalamus, leptin administration increases α2-AMPK 
phosphorylation at S491, which decreases AMPK activity. Mice 
lacking α2-AMPK in POMC neurons become obese due to dys-
regulated food intake and decreased energy expenditure (most 
likely via altered glucose sensing), while deletion of α2-AMPK 
in NPY/AgRP neurons results in an age-dependent lean pheno-
type (154). S6K was shown to form a complex with α2-AMPK, 
resulting in phosphorylation on S491 (158). Blocking α2-AMPK 
S491 phosphorylation increases hypothalamic AMPK activity, 
food intake, and body weight (158). Thus, mTOR-S6K signaling 
serves as an important signaling pathway upstream of AMPK in 
hypothalamic leptin signaling.
Other ObRb Signaling Pathways
Mice with replacement of all three ObRb tyrosines with phenyla-
lanines (ObRb3F) are slightly less obese than db/db mice and show 
significantly ameliorated glycemic control and fertility, illustrat-
ing that ObRb exerts crucial metabolic actions not only through 
ObR tyrosine-dependent but also ObR tyrosine-independent 
mechanisms (159). Interestingly, mice expressing a truncated 
ObRb mutant (ObRb∆65c), that retains JAK2 activity but lacks all 
ObRb tyrosines, have a similar phenotype as db/db mice showing 
obesity, diabetes, and infertility (160). Thus, the improved phe-
notype of ObRb3F mice compared to ObR∆65c mice reveals that 
JAK2-autonomous signaling is not sufficient to mediate these 
improvements. These data suggest the existence of non-canonical 
signaling pathways that may emanate from an uncharacterized 
ObRb site, independent of phosphorylation.
During the last few years, a role for several kinases in hypo-
thalamic leptin signaling was proposed. Rho-kinase 1 (ROCK1) 
regulates leptin’s effect on body weight homeostasis by binding 
and activating JAK2. ROCK1 increases JAK2 phosphorylation 
and downstream activation of STAT3 and Foxo1. Mice lacking 
ROCK1 in either POMC or NPY/AgRP neurons, display impaired 
leptin sensitivity and obesity (161). A role for the RIIβ regulatory 
subunit of PKA (cyclic AMP-dependent protein kinase A) in 
modulating the magnitude and duration of ObRb signaling was 
also demonstrated (162). Mice lacking this PKA subunit display 
reduced adiposity and resistance to DIO. Recently, Cdc2-like 
kinase 2 (CLK2) activity was proven to be regulated by leptin in 
a PI3K-dependent manner and reduction of CLK2 expression in 
the hypothalamus was sufficient to abolish the anorexigenic effect 
of leptin (163).
LEPTIN RESISTANCE: POSSIBLE 
MECHANISMS
The discovery of leptin in 1994 generated high expectations for its 
potential use as a therapeutic to combat obesity. However, obese 
individuals were found to be refractory to leptin therapy (164, 
165). In fact, obesity is commonly accompanied with elevated 
circulating leptin levels (hyperleptinemia) in proportion to the 
increased body fat mass. This paradox is referred to as leptin 
resistance and the underlying mechanism is multifactorial: 
impairment in ObRb signaling, hypothalamic neuronal wiring, 
leptin transport into the brain and ObR trafficking, ER stress and 
inflammation (16).
Negative Regulation of ObR Signaling
Leptin signaling is negatively regulated by SOCS3 and phos-
phatases, such as protein tyrosine phosphatase 1B (PTP1B), 
T-cell PTP (TCPTP), and RPTPϵ. Their hypothalamic expression 
levels are elevated in obesity and thus might contribute to the 
development of leptin resistance (166–168).
Members of the SOCS family are negative regulators of the 
JAK/STAT pathway. Leptin signaling via ObRb Y1138 and STAT3 
rapidly induces SOCS3 expression (92, 166, 169). SOCS3 in turn 
will initiate a negative feedback loop by binding ObRb Y985, 
inhibiting further phosphorylation/activation of JAK2 (166, 
170, 171). Immunohistochemical studies suggest that the ARC 
is selectively leptin resistant in DIO mice and that this may be 
caused by elevated SOCS3 expression (172). Neuron-wide dele-
tion of SOCS3 leads to enhanced leptin-induced hypothalamic 
STAT3 phosphorylation and POMC induction, resulting in a 
more pronounced suppression of food intake, body weight loss, 
and an attenuation of diet-induced leptin resistance compared 
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to wild-type mice (173). Specific deletion of SOCS3 in POMC 
neurons improves leptin sensitivity and glucose homeostasis 
(174). Consistently, increased SOCS3 expression in POMC neu-
rons results in impaired STAT3 signaling with subsequent leptin 
resistance and obesity (175). Likewise, mice overexpressing a 
constitutively active version of STAT3 in POMC neurons show 
elevated SOCS3 expression and develop obesity as a result of 
hyperphagia and decreased POMC expression accompanied by 
central leptin resistance (176). A temporal and spatial pattern in 
leptin responsiveness was demonstrated before (177), and more 
recently, it was shown that SOCS3 activation in AgRP neurons 
precedes that of POMC and other hypothalamic neurons in the 
development of DIO (178).
Unexpectedly, SOCS3 upregulation in ObRb-expressing neu-
rons does not lead to obesity, but rather a more lean phenotype 
(175). This may result from a compensatory increase in basal 
STAT3 expression and a corresponding increase in pSTAT3 levels 
after leptin treatment (175). However, inactivation of SOCS3 in 
ObRb-expressing cells protects mice from diet-induced insulin 
resistance, indicating that the regulation of leptin signaling by 
SOCS3 orchestrates diet-induced changes on glycemic control 
(179). Recently, ObRb-specific SOCS3−/− mice were studied in 
fasting and refeeding conditions. These mice exhibit increased 
leptin sensitivity in the hypothalamus and show attenuated food 
intake and weight regain after 48 h of fasting by a lower transcrip-
tion of orexigenic neuropeptides (180).
Protein tyrosine phosphatase 1B is localized to the cytoplas-
mic face of the ER and inhibits leptin signaling by binding and 
dephosphorylating JAK2 (181, 182). Mice with PTP1B-deficiency 
in the whole brain, ObRb expressing cells, or POMC neurons 
are lean, leptin hypersensitive, and display improved glucose 
homeostasis, supporting an antagonistic role for PTP1B in hypo-
thalamic leptin signaling (121, 183, 184). Moreover, the impact 
of PTP1B on energy homeostasis seems to rely on hypothalamic 
ObRb signaling as the reduced adiposity seen after hypothalamic 
PTP1B depletion is reversed by the concomitant hypothalamic 
deletion of ObRb (185).
Tyrosine phosphatases (PTPs) such as TCPTP and RPTPϵ 
were demonstrated to modulate ObR signaling (186), since 
genetic ablation of neuronal TCPTP or whole-body RPTPϵ 
enhances leptin sensitivity (167, 186, 187). Other PTPs including 
SHP2 and PTEN may also have regulatory functions in ObRb 
signaling and were briefly discussed above.
Hypothalamic Circuitry
Beyond leptin’s regulation of POMC and NPY/AgRP neurons 
on a transcriptional level, leptin can have a direct effect on these 
cells by altering neuronal firing (87). In addition, several lines 
of evidence have shown that the neuronal connectivity between 
specific subpopulations of hypothalamic and extra-hypothalamic 
neurons implicated in the regulation of energy balance is chang-
ing in response to high-fat diet (HFD) or metabolic hormones, 
such as leptin (188). For example, leptin treatment of ob/ob mice 
induces synaptic changes that precede the reduction in food 
intake and subsequent decrease in body weight (189). Although 
POMC and NPY/AgRP neurons in the ARC are considered to 
be the main targets of leptin, the majority of ObRb-expressing 
neurons lie outside the ARC in other central nervous system 
(CNS) regions known to modulate energy balance (88). This 
is underscored by the obese phenotype observed after deletion 
of ObRb in neurons, such as GABAergic neurons and NOS-1 
(nitric oxide synthase-1) expressing neurons (190, 191). Growing 
evidence points to a critical role of astrocytes in orchestrating 
the hypothalamic response to metabolic cues by participating in 
processes of synaptic transmission and plasticity (192). Impaired 
ObR signaling in astrocytes leads to an altered glial morphology, 
increases the number of synapses onto POMC, and NPY/AgRP 
neurons and blunts leptin-induced anorexia (193).
Defective Leptin Transport
To enter the brain, circulating leptin has to cross the BBB. During 
obesity, the cerebrospinal fluid/serum leptin ratio is decreased, 
indicating impairment of leptin transport (194, 195). Leptin is 
actively transported across the BBB in a saturable manner (196). 
The short ObR isoform, ObRa is believed to be implicated in 
this process (197, 198). However, more recent data contradict 
this theory. ObRa−/− mice show only a small decrease in leptin 
responsiveness, suggesting that ObRa binding is not the only way 
by which leptin accesses the CNS (199). Moreover, pre-treatment 
with an ObR-neutralizing antibody, to directly examine the 
involvement of endothelial ObR in leptin transport, did not alter 
leptin transport in an in vitro BBB model (200). A role for megalin 
(or LRP2, low-density lipoprotein receptor-related protein-2) as 
a leptin transporter in the choroid plexus has been suggested (see 
also further) (200, 201).
The contribution of defective leptin transport to central leptin 
resistance remains unclear. Recently, it was demonstrated that 
the median eminence serves as the route through which leptin 
is transported into the hypothalamus, and that tanycytes act as a 
transport checkpoint. Peripherally administered leptin sequen-
tially activates ObRb in median eminence tanycytes followed by 
neurons in the medio-basal hypothalamus (MBH) in a process 
that requires tanycytic ERK signaling (202). In obese mice (db/db 
or DIO) leptin accumulates in the median eminence and fails to 
reach the MBH, while triggering ERK signaling in tanycytes with 
epidermal growth factor (EGF) reestablishes leptin transport and 
its activation of MBH neurons (202).
Leptin Receptor Trafficking
The amount of signaling-competent ObRb on the cell surface is 
determined by the balance between receptor synthesis, transport 
to the plasma membrane, internalization, recycling, degradation, 
and ectodomain shedding. At steady state, the ObRb is mainly 
retained in the Golgi complex or in a post-Golgi intracellular 
compartment, resulting in low levels at the cell surface, from 
where it undergoes constitutive removal via ligand-independent 
endocytosis leading to lysosomal degradation with no evidence 
of recycling (53). Feeding seems to control ObRb expression 
since ObRb levels in the ARC are increased after fasting and 
decreased by refeeding. Leptin increases ObRb expression in the 
ARC, but not after high-fat feeding (203). However, overexpres-
sion of ObRb in POMC neurons renders mice more susceptible 
to DIO, further underlining the importance of correct ObRb 
expression (204).
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Endospanin 1 [also known as Ob-RGRP (ObR gene-related 
protein) or LEPROT (leptin receptor overlapping transcript)], 
whose expression is genetically linked to the ObRb transcript, 
negatively controls ObRb cell surface expression (205). 
Endospanin 1 interacts with ObRb and targets ObRb from 
endosomes to lysosomes, thereby increasing its degradation 
(206). Hence, endospanin 1 silencing in the ARC is sufficient to 
prevent or reverse the development of obesity after high-fat diet 
in lean or fully obese mice, respectively (205, 207).
Our group identified the E3 ubiquitin ligase RNF41 (Ring 
Finger Protein 41) as an interaction partner of the ObRb complex 
(17). RNF41 acts as a key regulator of basal cytokine receptor traf-
ficking, proteolytic processing, and signaling. RNF41 controls the 
constitutive intracellular trafficking of the ObRb, by preventing 
its lysosomal receptor degradation, and concomitantly enhancing 
receptor ectodomain shedding by the metalloprotease ADAM10 
(17). We further demonstrated that this results from RNF41-
dependent ubiquitination and suppression of the deubiquitinat-
ing enzyme USP8, which abrogates ESCRT-0 functionality and 
accounts for the rerouting of cytokine receptors (208).
Accumulating evidence suggests that the neuronal cilia basal 
body complex acts as a platform for ObRb signaling. Neuronal 
cilia lengths were selectively reduced in the hypothalamus of 
obese mice with leptin deficiency and leptin resistance, while 
treatment of hypothalamic neurons with leptin-stimulated cilia 
assembly via inhibition of PTEN and glycogen synthase kinase 
3β (GSK3β) (209, 210). Moreover, mice with short hypothalamic 
cilia exhibit increased food intake, decreased energy expenditure, 
and attenuated anorectic responses to leptin, which indicates that 
leptin-induced cilia assembly is essential for sensing leptin by 
hypothalamic neurons (209). Bardet–Biedl syndrome (BBS) pro-
teins form the stable BBSome complex, which mediates protein 
trafficking to the ciliary membrane (211). The BBSome influences 
energy homeostasis through the control of ObRb transport to the 
cell surface expression as targeted disruption of the BBSome by 
deleting BBS1 in ObRb-expressing cells causes obesity in mice 
(212, 213). Suppression of another ciliary gene, retina pigmen-
tosa GTPase regulator-interacting protein-1 (RPGRIP1L), in 
neuronal cultures decreases localization of ObRb near the cilium 
and activation of the downstream signaling cascade (214). Like 
BBS proteins, RPGRIP1L interacts with the ObRb and mediates 
its trafficking to the periciliary area (215). Mice hypomorphic for 
RPGRP1L exhibit hyperphagic obesity as the result of diminished 
leptin sensitivity in ObRb-expressing neurons (216).
ER Stress and Inflammation
Several studies have provided evidence that ER stress and the 
activated adaptive unfolded protein response (UPR) impair lep-
tin signaling and are highly increased in hypothalamic neurons 
in the context of obesity (217, 218). Reducing hypothalamic ER 
stress by chemical and natural chaperones can re-establish leptin 
sensitivity (217, 219, 220). Xbp1s (spliced X-box binding protein 
1) is one of the ER-stress-induced genes and neuron-specific 
Xbp1−/− mice have ER stress, severe hyperleptinemia, leptin 
resistance, and obesity (217). In contrast, induction of Xbp1s in 
POMC neurons alone is sufficient to protect against DIO and to 
improve leptin sensitivity by suppressing SOCS3 and PTP1B, 
even in the presence of strong ER stress activators (221). Several 
mechanisms are suggested to bridge HFD-induced ER stress to 
impaired ObR signaling (222). Overnutrition atypically activates 
IKKβ-NFκB signaling in the hypothalamus through ER stress 
responses, which implies a connection between ER stress and 
hypothalamic inflammation (218). Indeed, obesity seems to be 
associated with low-grade chronic inflammation (223). Saturated 
fatty acids, which are elevated in obesity, are able to bind and 
activate toll-like receptor 4 (TLR4) and inhibition of TLR4 or 
neuronal deletion of the TLR adaptor molecule MyD88 protects 
from HFD-induced leptin resistance and obesity (224–226). 
Inhibition of IKKϵ, a downstream molecule of NFκB signaling, 
reduces leptin resistance by restoring JAK2-STAT3 and PI3K 
signaling in the hypothalamus of HFD-fed mice (227).
It was recently shown that disruption of mitochondria–ER 
contacts may also contribute to leptin resistance development 
in POMC neurons. Mitochondrial-ER contacts are decreased in 
POMC neurons of mice receiving HFD (228). Furthermore, dele-
tion of PPARγ in POMC neurons enhances mitochondrial-ER 
interactions and sensitizes POMC neurons to leptin during HFD 
(229). On the other hand, mice with a POMC-specific deletion 
of MFN2 (mitofusin 2), a key protein for mitochondrial fusion 
and the formation of ER–mitochondria contacts, display a loss of 
these interactions, defective POMC processing, ER stress-induced 
leptin resistance, and obesity (228). In contrast, ablation of 
mitofusins in NPY/AgRP neurons disrupts mitochondrial fusion 
without inducing ER stress and alleviates HFD-induced obesity 
(230). These findings indicate the importance of mitochondrial 
dynamics in hypothalamic neurons during the establishment of 
DIO.
Redefine the View on “Leptin 
Resistance”?
Recently, Ottaway et al. reported that central or peripheral admin-
istration of an ObR antagonist induces comparable changes in 
food intake, body weight, and hypothalamic POMC and SOCS3 
expression in lean and DIO mice, illustrating that endogenous 
ObR signaling may not be reduced in the context of DIO, thus 
challenging the established concept of leptin resistance under 
dietary-induced conditions (231). More efforts are required to 
further comprehend the link between the different mechanisms 
mentioned above, and the precise sequence of appearance of the 
alterations, discriminating between causes and consequences 
(232). Moreover, many other nutrient signals, such as insulin and 
ghrelin, contribute to the control of energy homeostasis. Cross-
talk and redundancy between these signals complicate the precise 
assessment of the contribution of leptin-mediated signaling in 
the context of leptin resistance and obesity.
LEPTIN SIGNALING BEYOND THE ObR: 
CROSS-TALK AT THE CELLULAR 
SURFACE
Several independent lines of evidence suggest that leptin 
signaling in the brain or the periphery can be different. In a 
first example, Nizard and colleagues reported the pregnancy 
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of a morbidly obese patient with a rare ObR mutation (233). 
Normally, such loss-of-function mutations have been linked to 
infertility in humans and rodents (29, 234). Despite neonatal 
hypoglycemia, the child’s growth and development have been 
normal (233). Second, a serine to leucine mutation on position 72 
in leptin hampers the secretion, but not the expression of leptin 
in adipose tissue in a 14-year-old child of non-obese Austrian 
parents (235). The child showed signs of a hypogonadotropic 
hypogonadism, but in contrast to previous studies only mild 
obesity and a normal T cell responsiveness. Third, a spontaneous 
splice-mutation causes the deletion of the complete IGD domain 
in fatt/fatt mice (236). These animals are hyperphagic and obese, 
but show minimal changes in size and cellularity of the thymus 
and respond comparable to wild-type animals to concavalin A in 
a model for autoimmune hepatitis. Finally, treatment of healthy 
mice with a IGD-specific neutralizing nanobody induced clear 
weight gain and hyperinsulinemia, but failed to block develop-
ment of experimentally induced autoimmune multiple sclerosis, 
arthritis, and hepatitis (236).
Cross-talk with other (cytokine) receptors could explain this 
observed uncoupling of leptin’s central and peripheral functions. 
In a simplistic view, a cytokine triggers intracellular signaling by 
binding and activation of a cognate homo- or heteromeric receptor 
pair. However, when combined, cytokines, hormones, and other 
stimuli might have additive, synergistic, or antagonistic effects. 
This so-called “cross-talk” does not only occur at the level of 
signaling pathways but also at the cell surface between cytokines, 
hormones, and their receptors. The process that a certain cytokine 
activates another receptor complex is called cross-activation. At 
the moment, it is mostly unclear how a cytokine discriminates 
between different options, but cell-specific co-expression is likely 
a determining factor.
At the cell surface, the leptin:ObR system can interact with the 
epidermal growth factor receptor (EGFR), estrogen receptor alpha 
(ERα), insulin-like growth factor I receptor (IGF-IR), lipoprotein 
receptor-related protein 1 and 2 (LRP1 and LRP2), and vascular 
endothelial growth factor receptor (VEGFR). Studies describing 
ObR cross-talk and cross-activation are summarized in Table 1.
Epidermal Growth Factor Receptor
The EGFR is a single membrane-spanning receptor with a cyto-
plasmic tyrosine kinase domain. This receptor can be activated 
not only by its “natural” ligands, including EGF, transforming 
growth factor-α (TGF-α), heparin-binding EGF-like growth fac-
tor, amphiregulin , and epiregulin but also by cross-activation by 
G-protein-coupled receptors, the tumor necrosis factor receptor, 
or IGF-IR [reviewed in Ref. (259)]. ObR:EGFR cross-talk and 
cross-activation is not restricted to cancer cell lines, but could 
also be demonstrated in muscle, salivary gland, and mucosal cells 
and in rat kidneys (see Table 1). The cross-talk often involves 
the activity of ERK and Src kinases and can be blocked by EGFR 
kinase inhibitors. Both ObR long and short forms are able to 
phosphorylate the EGFR, suggesting that this cross-activation is 
independent of downstream ObR signaling (244). It was suggested 
that this cross-talk depends on the proteolytic release of EGFR 
ligands as broad-spectrum matrix metalloproteinase inhibitor 
(e.g., GM6001) blocks the leptin-induced effects. However, this 
pathway likely does not explain the rapid (within 5 min) and 
transient increase in EGFR tyrosine phosphorylation by leptin 
in, for example, rat aortic smooth muscle cells (241).
ERα
A significant co-expression between ObR and ERα and a func-
tional cross-talk between the leptin and estrogen signaling net-
works are associated with breast tumor progression [reviewed in 
Ref. (260)]. Leptin not only controls ERα and aromatase mRNA 
expression both in vitro and in vivo and in an ERK and STAT3-
dependent manner (247, 249, 250), one report shows that it can 
directly cross-activate ERα in the absence of cognate ligand (248).
Insulin-Like Growth Factor I Receptor
Insulin-like growth factor I receptor is an α2: β2 disulfide-linked 
receptor that shares more than 50% of overall sequence homology 
with the IR. It is overexpressed in 50% of primary breast tumors 
compared with normal tissue (261), and IGF-IR inhibition reduces 
cancer growth and metastasis in vivo (262). Saxena et al. and Ozbay 
et al. independently demonstrated the ObR:IGF-IR cross-talk in 
breast cancer cells: both IGF-I and leptin phosphorylate the recip-
rocal receptor, ObR and IGF-IR can be co-immunoprecipitated, 
and combined treatment increased proliferation, invasion, and 
migration of breast cancer cells (251, 252).
LRP1/LRP2
LRP1 is highly expressed in neurons of the CNS and plays a role in 
lipoprotein metabolism, neurotransmission, synaptic plasticity, 
and cell survival (263). Liu et al. showed that conditional deletion 
of LRP1 results in an obese phenotype, characterized by increased 
food intake, decreased energy expenditure, and hampered leptin 
signaling. LRP1 directly interacts with ObR and is necessary for 
STAT3 activation (253).
LRP2 or megalin is a large glycoprotein abundantly expressed 
at the apical membranes of proximal tubule cells that reabsorb 
and metabolize proteins filtered by glomeruli in the kidney (264). 
A role of LRP2 in leptin clearance (254, 256), and/or transport 
over the BBB has been suggested (see above) (255).
Vascular Endothelial Growth Factor 
Receptor
Vascular endothelial growth factor receptor and its receptor 
play a crucial role in the angiogenic process in physiologic and 
pathological scenarios (265). In human umbilical vein endothelial 
cells and porcine endothelial cells, leptin trans-phosphorylates 
VEGFR-1 and VEGFR-2, induces cyclo-oxygenase-2 and Notch 
signaling, proliferation and tube formation (257, 258).
LEPTIN SIGNALING BEYOND THE ObR: 
CROSS-TALK BETWEEN DOWNSTREAM 
SIGNAL CASCADES
Cross-talk does not only occur at the receptor level (receptor 
co-complexes, cross-activation) but also more downstream at 
the level of activated kinases and transcription factors or due to 
leptin-dependent expression of other cytokines.
TABLE 1 | Overview of studies describing ObR cross-talk and/or cross-activation (see text for more details).
Background Model Effects Reference
Epidermal growth factor 
receptor (EGFR)
In vitro Gastric cancer cells (MKN28 and MKN74) Leptin-induced EGFR phosphorylation (237)
EGFR inhibitor AG1478 blocks leptin-induced JAK2 and ERK1/2 activation
In vitro Human breast cancer cells (MCF7 and MDA-MB-231) Leptin induces clonogenicity, anchorage-independent growth, migration, and (238)
upregulation of survivin and Notch-I expression and EGFR phosphorylation
In vitro Esophageal adenocarcinoma cells (OE33, OE19, BIC-1, 
and FLO)
Leptin induces proliferation, inhibits apoptosis, and enhances EGFR and ERK1/2 phosphorylation (239, 240)
EGFR inhibitors AG1478, and PD98059 block these effects
In vitro Rat aortic smooth muscle cells Leptin induces EGFR and ERK1/2 phosphorylation and endothelia-1 expression (241)
EGFR inhibitor AG1478 blocks leptin-induced ERK1/2 phosphorylation and endothelia expression
In vitro Gastric mucosal cells Leptin induces EGFR and cPLA2 phosphorylation and protects against ethanol cytotoxicity (242)
EGFR inhibitor AG1478 blocks phosphorylation events and the protection
In vitro Rat sublingual salivary gland acinar cells Leptin induces EGFR and cPLA2 phosphorylation and protects against ethanol cytotoxicity (243)
EGFR inhibitor AG1478 blocks phosphorylation events and the protection
In vitro Transfected Hek293T cells Both long and short ObR forms trans-phosphorylate and activate EGFR (244)
In vivo Rat kidneys Leptin induces Na+, K+-ATPase activation, H2O2 excretion, and ERK1/2 phosphorylation (245)
EGFR inhibitors, AG1478 and PD98059, block these effects
ERα In vitro Human breast cancer cells (MCF7 and MDA-MB-231) ERα downregulation abolishes leptin-induced STAT3 phosphorylation independent of ERα ligands (246)
ERα binds to JAK2 and STAT3 thereby increasing kinase activity and cell viability
In vitro Human breast cancer cells MCF7 Leptin enhances aromatase expression via AP-1 and STAT3 and ERK1/2 dependent (247)
In vitro Human breast cancer cells MCF7 and transfected HeLa 
cells
Leptin induces ERα nuclear localization and controls ERα expression on mRNA and protein level (248)
Leptin treatment potentiates estradiol-induced activation of ERα
In vitro Human breast cancer cells MCF7 Leptin increases ERα expression (249)
Ex vivo Breast cancer patients Significant correlation between ObR and ERα levels
In vivo Mouse MCF7 xenografted nude mice Leptin increases ERα and decreases ERβ levels on mRNA and protein level (250)
Insulin-like growth factor 
I receptor (IGF-IR)
In vitro Human breast cancer cell lines (MDA-MB-231, BT474, and 
SKBR3)
ObR and IGF-IR can be co-immunoprecipitated
Unidirectional: IGF-I induced ObR phosphorylation depends on IGF-IR kinase activity
(251)
In vitro Human breast cancer cells (MCF7, MDA-MB-231, and 
MDA-MB-468)
Bidirectional: IGF-I induced ObR phosphorylation, leptin IGF-IR phosphorylation
Leptin and IGF-I co-treatment synergistically cross-activated EGFR
(252)
EGFR cross-activation promotes metastatic properties, invasion, and migration
LRP1 In vivo Lrp1 forebrain knockout mice Conditional deletion of LRP1 decreases leptin signaling and results in an obese phenotype (253)
LRP1 interacts with ObR and is required for STAT3 phosphorylation
LRP2 In vivo and 
in vitro
Mice, rats, Rhesus Macaques, and yolk sac L2 cells PET imaging illustrates that leptin is rapidly taken up by LRP2 in the renal tubules
Leptin uptake is also mediated by LRP2 in L2 cells
(254)
In vivo Wistar rats LRP2 mediates transport of leptin through the choroid plexus (255)
Choroid plexus LRP2 expression correlates with leptin uptake
In vivo and 
in vitro
Wistar rats and yolk sac L2 cells Labeled leptin in rats is filtered by glomeruli and internalized by proximal convoluted tubules
LRP2 binds leptin in a Ca2+-dependent manner and mediates internalization and degradation
(256)
Vascular endothelial 
growth factor receptor 
(VEGFR)
In vitro Human umbilical vein endothelial cells (HUVEC) Leptin induces HUVEC proliferation, cyclo-oxygenase-2 expression, and VEGFR2 phosphorylation (257)
Inhibition of VEGFR-2 kinase activity blocks the leptin-induced effects
In vitro Human umbilical vein and porcine aortic endothelial cells Leptin trans-phosphorylates VEGFR-1 and VEGFR-2 (258)
Leptin induces Notch signaling, proliferation, and tube formation in these endothelial cells
Effects can be blocked by Notch and VEGFR inhibitors
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Leptin–Insulin
Both leptin and insulin elicit strong anorectic responses within 
the ARC and their central administration, which mimics a 
state of energy surplus, inhibits food intake, and decreases 
body weight (266). One prevailing view is that different POMC 
neurons exist and that leptin and insulin may act on distinct 
POMC neuronal subsets (127). However, many studies demon-
strate cross-talk between leptin and insulin signaling at many 
levels [reviewed in Ref. (267)]. The insulin pathway, after insulin 
binding to the IR and activation of the IRS proteins, converges 
with the leptin pathway at the same point, the activation of 
PI3K, to modulate body weight and glucose homeostasis (268). 
Also, both leptin and insulin regulate the AMPK pathway in 
the hypothalamus and inhibit AMPK activation and its down-
stream targets (153, 154). Recently, it was shown that insulin can 
potentiate leptin-induced STAT3 activation by the induction of 
GRP78 (glucose-regulated protein 78), a UPR chaperone that is 
required to maintain ER capacity and protect against ER stress 
(269). Strikingly, ICV administration of leptin in mice devoid 
of insulin and lacking ObRb demonstrates that concomitant 
re-expression of ObRb only in hypothalamic GABAergic and 
POMC neurons is sufficient to fully mediate the anti-diabetic 
actions of leptin in insulin deficiency (270). Likewise, cellular 
insulin resistance disrupts leptin-mediated control of neuronal 
signaling and transcription (271).
NILCO (Notch, IL-1, and Leptin Cross-talk 
Outcome)
Functional cross-talk between leptin, IL-1, and Notch signaling 
(NILCO) is found in breast cancer cells and could represent the 
integration of developmental, pro-inflammatory, and pro-angio-
genic signals which are critical for leptin-induced breast cancer 
cell proliferation/migration and tumor angiogenesis. Inhibition 
of leptin signaling significantly reduces the establishment and 
growth of breast cancer and simultaneously decreases the levels 
of VEGF/VEGFR2, IL-1 and Notch (272–274). Therefore, inhibi-
tion of leptin–cytokine cross-talk might serve as a preventative 
or adjuvant measure to target breast cancer, particularly in obese 
women.
Cross-talk with Pro-inflammatory 
Cytokines
Pro-inflammatory cytokines may have differential roles in hypo-
thalamic leptin signaling. As mentioned before, overnutrition 
leads to increased expression of pro-inflammatory cytokines, 
such as tumor necrosis factor-α (TNF-α), IL-1β, and IL-6 (223, 
275). Lack of TNFR1 mitigates leptin resistance under HFD 
conditions, while ICV co-injection of TNFα partially blocks lep-
tin’s anorexigenic effect through the inhibition of PI3K–Foxo1 
signaling (276, 277). Conversely, central injection of an IL-1R 
antagonist or IL-1R1 knock-down blunts the suppression of 
food intake in response to leptin (278). Likewise, central infu-
sion of IL-6 enhances hypothalamic STAT3 phosphorylation 
and suppresses hypothalamic IKKβ activation and hyperphagia 
in DIO (279).
Toll-Like Receptor 4
Toll-like receptor 4 and ObRb activation seem to converge at a 
common signaling point in the hypothalamus. LPS, a ligand of 
TLR4, stimulates PI3K and STAT3 signaling pathways in cells 
expressing ObRb. Genetic deletion of the PI3K p110β catalytic 
subunit in ObRb-expressing cells leads to blunted suppression of 
food intake by LPS which demonstrates that lowered food intake 
during an inflammatory challenge depends on the PI3K pathway 
activated by cytokines and leptin in hypothalamic neurons 
(280). Moreover, NFκB signaling in POMC neurons is activated 
by leptin and mediates leptin-stimulated POMC transcription, 
indicating that hypothalamic NFκB also serves as a downstream 
transcription factor of the ObRb (281). Increased hypothalamic 
POMC promoter methylation in mice with DIO limits NFκB 
binding, which limits the ability of leptin to increase POMC 
expression (282).
FUTURE PERSPECTIVES
It is more than 20  years ago that leptin and its receptor have 
been identified as key regulators of body weight and energy 
homeostasis. However, the hormone mostly failed in the clinic to 
treat obesity due to the fact that obese people are almost always 
hyperleptinemic and resistant to leptin. The observation that 
leptin has functions in immunity, hematopoiesis, angiogenesis, 
reproduction, and BP, and is involved in the pathology of, e.g., 
autoimmune diseases and cancers, reopened the interest in leptin 
and ObR-based therapeutics. Current strategies, including leptin 
mutants, leptin peptide antagonists, neutralizing antibodies, and 
soluble receptors, were shown to be effective in the treatment 
of several autoimmune diseases and in some cancer models 
[reviewed in Ref. (283)]. Their clinical application is, however, 
hampered by the unwanted weight-gain (10–15% per week in 
rodent models) upon treatment.
The ability of the ObR to interact with other receptor systems 
at the receptor level or intracellulary illustrates that the leptin 
receptor complex may be “heavier” than expected. This creates 
new exciting opportunities including the possibility to uncouple 
leptin’s central role in weight regulation and its peripheral func-
tions. More in-depth insights in these complex leptin/ObR acti-
vation and downstream signaling mechanisms may ultimately 
allow the design of selective antagonists.
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